Towards rational use of inhaled Nitric Oxide in preterm babies

inhaled nitric oxide in preterm infants: an updated meta?analysis

background: respiratory distress syndrome and persistent pulmonary hypertension of the newborn are common acquired diseases in preterm infants. in the past several years, randomized controlled trials (rcts) have indicated that inhaled nitric oxide (ino) can potentially lower for both the incidence of bronchopulmonary dysplasia (bpd) and mortality in affected infants. other research has, however...

Inhaled nitric oxide in preterm infants.

OBJECTIVES To systematically review the evidence on the use of inhaled nitric oxide (iNO) in preterm infants born at or before 34 weeks gestation age who receive respiratory support. DATA SOURCES We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Studies (CENTRAL) and PsycInfo in June 2010. We also searched the proceedings of the 2009 and 2010 Pediatric Academic Societie...

Inhaled nitric oxide in the treatment of preterm infants.

Inhaled nitric oxide (iNO) has been used successfully in select term and near-term infants with respiratory failure. The use of iNO in the premature infant population, however, remains controversial. This article will review some of the current literature regarding the use of iNO in premature infants and discuss current recommendations and future research directions.

Inhaled nitric oxide use in newborns.

Inhaled nitric oxide (iNO) is a pulmonary vasodilator that plays a major role in regulating vascular muscle tone. It has emerged as a treatment for hypoxemic respiratory failure in newly born infants that is associated with persistent high pulmonary vascular pressure and resultant right-to-left shunting of blood (persistent pulmonary hypertension of the newborn). Current evidence shows that iNO...

Neonatal Use of Inhaled Nitric Oxide